Yep, the abstract put it in context :......CD19 targeting...

Yep, the abstract put it in context :

......CD19 targeting chimeric antigen receptor (CAR) T cell therapy has demonstrated impressive clinical outcomes but translating this therapy to solid cancer has been met with various challenges, including the immunosuppressive microenvironment, on-target off-tumor toxicity, and antigen heterogeneity.

To date, CAR T cell therapies against HCC targeting antigens such as alpha-fetoprotein and glypican-3 have shown nominal efficacy in clinical trials. Therefore, development of novel and innovative therapeutic approaches against HCC are desperately needed to overcome the challenges and improve clinical outcomes. Oncolytic viruses (OV) are a novel and attractive form of immunotherapy due to the ability to target tumor cells selectively, even in the absence of tumor specific antigens, and deliver genes of interest for therapeutic intervention. We have harnessed this capability of OV and developed a chimeric vaccinia-based OV called CF33-CD19t (onCARlytics) that delivers a non-signaling, truncated CD19 (CD19t) antigen to solid tumors allowing CD19-specific T cells to target them......